PPP2R5B (Protein Phosphatase 2 Regulatory Subunit B5 Beta) encodes the B56β (also known as B56β or PR53) regulatory subunit of protein phosphatase 2A (PP2A), one of the most abundant serine/threonine phosphatases in the brain. The PPP2R5B gene is located on chromosome 14q32.31 and encodes a protein of approximately 515 amino acids. This regulatory subunit plays a critical role in targeting PP2A to specific substrates, particularly those involved in tau phosphorylation, synaptic plasticity, and neuronal survival. Dysregulation of PPP2R5B and resulting PP2A dysfunction is strongly implicated in the pathogenesis of Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative disorders characterized by tau pathology and synaptic failure 1.
The PPP2R5B gene spans approximately 30 kb and consists of 14 exons encoding the B56β protein. The gene is part of a family of five PPP2R5 genes (A, B, C, D, E) that encode different B56 isoforms with distinct expression patterns and substrate specificities 2. Alternative splicing generates additional variants with tissue-specific expression patterns.
The B56β protein contains:
The B56 subunits form heterotrimeric PP2A complexes consisting of:
This trimeric structure allows precise temporal and spatial regulation of PP2A activity toward specific substrates including tau, Akt, and synaptic proteins 3.
One of the most critical functions of B56β-containing PP2A complexes in neurons is the dephosphorylation of the microtubule-associated protein tau. Tau is abnormally hyperphosphorylated in Alzheimer's disease, leading to its aggregation into neurofibrillary tangles (NFTs) and consequent synaptic and neuronal loss 4.
B56β-PP2A dephosphorylates tau at multiple pathogenic sites including:
The activity of B56β-PP2A toward tau is regulated by multiple mechanisms including:
B56β-PP2A regulates several key signaling pathways relevant to neurodegeneration:
Akt Signaling: PP2A dephosphorylates Akt at Ser473, terminating pro-survival signals and linking metabolic status to neuronal viability 5.
MAPK/ERK Pathway: B56β-PP2A modulates ERK1/2 signaling, which is involved in synaptic plasticity and stress responses.
Wnt/β-catenin Pathway: PP2A-B56β dephosphorylates β-catenin, regulating its nuclear translocation and transcriptional activity in neuronal development and disease 6.
PP2A-B56β is enriched at synapses where it regulates:
The PP2A-B56β complex is particularly important for hippocampal synaptic plasticity and memory formation 7.
PP2A-B56β regulates apoptotic pathways by:
Dysregulation of PP2A-B56β can shift the balance toward apoptosis in vulnerable neurons.
PPP2R5B is widely expressed in the human brain with highest levels in:
In neurons, B56β localizes to:
Expression is regulated during development, with higher levels in embryonic brain that decrease postnatally, then increase again in aging.
PPP2R5B and PP2A dysregulation are strongly implicated in AD pathogenesis 8:
PP2A Activity Reduction: Post-mortem studies show 30-50% reduction in PP2A activity in AD brain tissue compared to age-matched controls. This reduction correlates with disease severity and neurofibrillary tangle burden.
B56β Expression Changes: Altered B56β expression and distribution in AD brain, with decreased synaptic localization and increased cytoplasmic accumulation.
Tau Hyperphosphorylation: Reduced PP2A-mediated tau dephosphorylation directly contributes to NFT formation. Several pathogenic tau phosphorylation sites are PP2A substrates.
Synaptic Failure: PP2A-B56β dysregulation contributes to synaptic plasticity deficits that correlate with cognitive decline.
Mechanistic Links:
PP2A dysfunction in PD involves:
Studies show decreased PP2A activity in PD substantia nigra, and genetic variants in PP2A may modify PD risk.
Frontotemporal Dementia (FTD): Tau-positive FTD shows similar PP2A dysregulation
Progressive Supranuclear Palsy (PSP): 4R tauopathies show PP2A alterations
Amyotrophic Lateral Sclerosis (ALS): PP2A dysfunction in motor neurons
B56 subunits including PPP2R5B can function as tumor suppressors. Loss of B56β expression has been reported in several cancers, and the gene may have context-dependent oncogenic or tumor-suppressive functions.
Given the central role of PP2A dysfunction in neurodegeneration, PP2A activators are being explored as disease-modifying therapies:
Small Molecule Activators:
Targeting PP2A Regulation:
PPP2R5B expression and PP2A activity measurements may serve as:
Genome-wide association studies have identified potential associations between PPP2R5B variants and:
Research is ongoing to identify rare pathogenic variants in PPP2R5B that may cause or modify neurodegenerative disease risk.
The PP2A-B56β complex plays a central role in regulating tau phosphorylation through a coordinated dephosphorylation cascade. Under normal physiological conditions, PP2A-B56β maintains tau in a dynamic equilibrium between phosphorylated and dephosphorylated states, which is essential for microtubule stability and neuronal function.
The dephosphorylation process involves:
In Alzheimer's disease, this cascade is disrupted at multiple points:
This results in tau hyperphosphorylation, NFT formation, and microtubule disassembly, contributing to synaptic loss and neuronal death.
PP2A activity is modulated by metal ions that can act as either activators or inhibitors:
Activators:
Inhibitors:
The interplay between metal homeostasis and PP2A function provides a mechanistic link between environmental metal exposure and neurodegenerative processes.
PP2A-B56β intersects with neuroinflammatory pathways in complex ways:
Microglial Activation: Pro-inflammatory cytokines (IL-1β, TNF-α) can inhibit PP2A activity, creating a feed-forward loop where inflammation promotes tau pathology.
NLRP3 Inflammasome: PP2A dephosphorylates components of the inflammasome, potentially limiting inflammatory damage.
TNF-α Signaling: PP2A-B56β dephosphorylates key components of the NF-κB pathway, providing a brake on neuroinflammation.
Understanding these interactions may reveal novel therapeutic targets that address both tau pathology and neuroinflammation simultaneously.